Jan 09, 2024 / 11:00PM GMT
Seth Schwartz J.P. Morgan-Analyst
Well, good afternoon, everyone, and welcome. My name is Seth Schwartz. I lead JP Morgan's Healthcare Investment Banking Business in Australia. It's a great pleasure to welcome Telix to the JP Morgan Conference again this year. And let me introduce Chris Behrenbruch, Managing Director and CEO, to take the presentation away.
Chris Behrenbruch Telix Pharmaceuticals Limited-Group CEO&MD
Thanks very much, Seth. And thank you to the JPM team, as always, for the invite, and to those in the room and online. Appreciate the opportunity to present the company to you.
So three parts to Telix as an overview, for those of you who may or may not know the company to a greater or lesser extent. First of all, we're a theranostic radiopharmaceutical company. That means that our core, we're a therapeutics company, but we believe in the importance of precision medicine and selecting patients for therapy. And I think that's something that regulators have fundamentally bought into as a critical requirement
Telix Pharmaceuticals Ltd at JPMorgan Healthcare Conference Transcript
Feb 15, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers